Below the list of publications by partners acknowledging PHGEN II is complied in alphabetic order. Other publication material can be found under "Publications" on the column right side of the page.
Dabrock P., M.A., "Individualisierte Medizin aus ethischer Sicht“, Conference: "Individualisierte Medizin", Organizer: Teltower Kreis, Berlin, Germany, 05 November 2009
Dabrock P., M.A., "Autonomie oder Gemeinwohl? Zur Grundspannung einer Public-Health-Genomics-Ethik“ , within lecture series "Konzepte des Humanen II" an der Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany, 03 December 2009
Dabrock P., M.A., "Individualisierte Medizin aus medizin- und sozialethischer Sicht", Cadenabbia-meeting of Konrad Adenauer Foundation "Medizin – Ethik – Recht: Medizin nach Maß. Individualisierte Medizin – Wunsch und Wirklichkeit", Cadenabbia, Italy, 10 September 2010.
Popova, St., K. Dokova, Kr. Aleksandrova, "Status and Possibilities for integration of Genomics and Public Health in Bulgaria”, the Session of Scientific Union, Varna, Varna, Bulgaria, October 2009
Cambon-Thomsen A., "Ethique et Genetique : Quels tests, comment, pourquoi faire? Internet : les enjeux", Séminaire Promesses et Dérives des Tests Génétiques le 2/02/2010, Supbiotech, Paris, France (intervenant invité), 2 February 2010
Cambon-Thomsen A., "Les controverses éthiques au cœur des controverses scientifiques: application au domaine de la production et de l’utilisation des données génétiques humaines", Intervenant invité, cycle de conférences "Communication, Science, Culture et Société", intitulé "Les controverses scientifiques pour comprendre la recherche?" ENS Lyon, France, February 2010
Cambon-Thomsen A., Rial-Sebbag E., "Tests génétiques en vente libre sur Internet : déterritorialisation des régulations bioéthiques et stratégies de développement commercial", Colloque « Santé et mobilités au Nord et au Sud : Circulations des acteurs, évolutions des pratiques » Toulouse, France, 16-18 Septembre 2009 (Communication orale)
Bertier G., Rial-Sebbag E., Julia S., Ducournau P., Cambon-Thomsen A., "French bioethics law in revision : what challenges for genetic testing regulation?" 5èmes assises de génétique humaine, Strasbourg, France, 28-30 January 2010 (Poster P194). M/S hors série no 1, vol. 26, January 2010, p92
Pigeon A., Rial-Sebbag E., Cambon-Thomsen A., "The network of influences between ethics, law and practices in regulation of genomic information: a 10 years overview" oral communication presented by E Rial-Sebbag, Ten years after: mapping the societal landscape of genomics. Amsterdam, the Netherlands, 27 - 28 May 2010
Julia S., Soulier A., Sanlaville D., Rial-Sebbag E., Keren B., Heron D., Till M., Edery P., Calvas P., Bourouillou G., Cambon-Thomsen A., "P01.08 Ethical aspects of Array Comparative Genomic Hybridisation (CGH) for mental retardation diagnosis and genetic counselling" Eur J Hum Genet, 2010, Vol 18 (Spp1) P44 (Poster) Eur Soc Hum Genet. Göttingen, Sweden June 11 – 14, 2010
Julia S., Soulier A., Cambon-Thomsen A., "Clinical geneticists tomorrow: Are quantity & diversity of information an opportunity or a trap?" Eur J Hum Genet, 2010, Vol 18 (Spp1) P51(Poster) Eur Soc Hum Genet. Göttingen, Sweden June 11 – 14, 2010 (Poster) P01.37
Ducournau P., Bulle A., Cambon-Thomsen A., Gourraud P., Rial-Sebbag E., "EP15.08 Direct to consumer genetic testing : marketing strategies and ethical and societal issues" Eur J Hum Genet, 2010, Vol 18 (Spp1) P398 (Poster) Eur Soc Hum Genet. Göttingen, Sweden June 11 – 14, 2010 (Poster)
Julia S., Soulier A., Cambon-Thomsen A., "From Research to Clinic : the clinician-patient relationship as a key of the high throughput technology transfer into clinic”, HUGO (Human Genome Organisation) meeting 2010. Montpellier, France, May 18-21, 2010 (Poster)
Ambrosino E., Meeting on “Public health in the 21st century: what should be the Agenda for Public Health in an era of Genome-based & Personalized Medicine?” Ickworth, UK, May 10-14, 2010
Ambrosino E., Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference “Infectious disease Genomics and Global Health” Hinxton, UK, September 12-15, 2010
Ambrosino E., workshop on Public Health Genomics: “Integration of genome-based knowledge and technologies to fight infectious diseases”, EUPHA conference, Amsterdam, the Netherlands, 13 November, 2010
Syurina E., Analysis of existing international legislative evidence in Public Health Genomics, 3rd Annual Meeting of NGFN-Plus and NGFN-Transfer in the Program of Medical Genome Research, Berlin, Germany, November 25-27, 2010
Lavinha J., Molecular epidemiology, Special topics in epidemiology, Faculty of Medicine, University of Lisboa, Lisboa, Portugal, 10 July, 2010
Møller, P., “Introduction to Inherited cancer. Nomenclature and definitions, Norwegian Group on Inherited Cancer annual meeting 2010, Tromsø, Norway, November 16, 2010.
Møller, P., “Norwegian guidelines for inherited cancers”, Norwegian Group on Inherited Cancer annual meeting 2010, Tromsø, Norway, November 17 2010
Møller, P., “Risk for breast cancer in kindreds with breast cancer and in BRCA mutation carriers”, Norwegian Group on Inherited Cancer annual meeting 2010, Tromsø, Norway, November 17, 2010
Møller, P., “PHGEN II and the Human Variome Project”, Norwegian Group on Inherited Cancer annual meeting 2010, Tromsø, Norway, November 17, 2010
Haslberger A., "Epigenetische Aspekte der Ernährung im Alter", Ernährung durch den Lebenszyklus, ÖGE-Jahrestagung 2010, Universität Wien, Wien, Austria, November 29, 2010
Haslberger A., "Epi-Genetik – Einfluss von Lebensstilfaktoren auf die Tumorentstehung", Empfehlungen zwischen Theorie und Praxis, Österreichische Gesellschaft für Psychoonkologie, Jahrestagung, Wien, Austria, September 22, 2010
Brand A (2009). Integrative genomics, personal-genome tests and personalized healthcare: the future is being built today. Commentary. Eur J Hum Genet 17(8):977-8
Brand A, Rosenkötter N, Schulte in den Bäumen T, Schröder-Bäck P (2009). Public Health Genomics. Die Zukunft wird heute gestaltet! Bundesgesundheitsblatt 52:665-676
Morre SA, Ouburg S, Perfa AS, Brand A (2009). The EU FP6 EpiGenChlamydia Consortium: contribution of molecular epidemiology and host-pathogen genomics to understanding Chlamydia trachomatis-related disease. Drug Today 45:7-13
Rosenkötter N, Vondeling H, Blancquaert I, Mekel OC, Kristensen FB, Brand A (2010). The contribution of health technology assessment, health needs assessment, and health impact assessment to the asessment and translation of technologies in the field of public health genomics. Public Health Genomics 14(1):43-52
Burke W, Burton H, Hall AE, Karmali M, Khoury MJ, Knoppers B, Meslin EM, Stanley F, Wright CF, Zimmern RL, Ickworth Group (2010). Extending the reach of public health genomics: what should be the agenda for public health in an era of genome-based and “personalized” medicine? Genet Med 12(12):785-91
Ricciardi W, Boccia S, Zimmern RL, Cassiman JJ, Schröder-Bäck P, Gurwitz D, Ibarreta D, Lavinha J, Patch C, Sasiadekl M, Ten Kate L, Brand A, Brand H. Lo sviluppo di politiche sanitarie per un'introduzione corretta delle technologie basate sul genoma nei servizi sanitari dell'Unione Europea. L'Arco di Giano 659-696, 2010
Schulte in den Bäumen T, Brand A. Public Health Genomics - Integrating Genomics and Epigenetics into National and European Health Strategies and Policies. Epigenetics and Human Health: Linking Hereditary, Environmental and Nutritional Aspects 267-278, 2010
Becla L, Lunshof JE, Gurwitz D, Schulte In den Bäumen T, Westerhoff HV, Lange BM, Brand A (2011). Health technology assessment in the era of personalized health care. Int J Technol Assess Health Care 27(2):118-26
Syurina E, Brankovic I, Probst-Hensch N, Brand A (2011). Genome-Based Health Lit-eracy: A New Challenge for Public Health Genomics. Public Health Genomics Journal 14:201-210
Brand A. (2011) Public health genomics – public health goes personalized? Editorial. Eur J Public Health 21(1):2-3
Brand A, Brand H (2011). Health Literacy and Public Health Genomics: Innovation Management by Citizens. Editorial. Public Health Genomics Journal 14:193-194
Cleeren E, Van der Heyden J, Brand A, Van Oyen H (2011). Public health in the genomic era: will Public Health Genomics contribute to major changes in the prevention of common diseases? Open Access Archives of Public Health 69(8)
Lal JA, Schulte in den Bäumen T, Morre SA, Brand A (2011). Public Health and Valorization of Genome-based Technologies: A new model. Open Access Journal of Translational Medicine 9:207
Lehrach H, Sudbrak R, Boyle P, Pasterk M, Zatloukal K, Müller H, Hubbard T, Brand A, Jameson D, Westerhoff HV (2011). ITFoM – the IT Future of Medicine. Open Access Procedia Computer Science Procedia Computer Science 7:26–29
Taneri B, Ambrosino A, van Os J, Brand A (2012). A new Public Health Genomics model for common complex diseases, with an application to common behavioral dis-orders. Open Access Personalized Medicine 9(1):29-38
Cesuroglu T, van Ommen B, Malats N, Sudbrak R, Lehrach H, Brand A (2012). Public health perspective: from personalized medicine to personal health. Open Access Per-sonalized Medicine 9(2):115-119
Syurina EV, Schulte in den Bäumen T, Feron FJM, Brand A (2012). Analysis of exist-ing international policy evidence in public health genomics: mapping exercise. Open Access Journal of Public Health Research | DOI: 10.4081/jphr.2012.e8
Brand A: Healthcare faces a paradigm shift. Bayer Forschungsmagazin, Edition 23 (2012), pp 38-39
Brand A (2012): Public Health Genomics and Personalized Healthcare: a pipeline from cell to society. Drug Metabolism and Drug Interactions, 27(3):121-123.
Brand A, Lal JA (2012): European Best Practice Guidelienes for Quality Assurance, Provision and Use of Genome-based Information and Technologies: the 2012 declaration of Rome. Drug Metabolism and Drug Intereactions, 27(3):177-182.
Angela Brand, 01.05.2009, WFPHA Istanbul/Turkey, “Public Health Genomics and International Activities”
Angela Brand, 08.05.2009, International Congress of Molecular Medicine Istanbul/Turkey, “Introduction to Public Health Genomics and Its Future Implications”
Angela Brand, 25.06.2009, EUFEP Baden/Austria, „Genetic Screening – What is the role of Public Health Genomics?”
Nuria Malats, 06.07.2009, CNIO Madrid/Spain, „Are we ready for massive scaling data integration in epidemiological studies”
Angela Brand, 07.07-2009, CNIO Madrid/Spain, “Cancer genomics, personalized healthcare, and the role of public health genomics”
Stefania Boccia, 24.08.2009, ICEM Florence/Italy, “Public Health and genomic epidemiology”
Angela Brand, 24.08.2009, ICEM Florence/Italy, “The Public Health Genomics European Network”
Angela Brand, 28.8.2009, Kick-off Meeting Swiss PHGEN NTF Zürich/Switzerland, “Introductiomn to Public Health Genomics and International Efforts”
Angela Brand, 24.08.2009, Swiss Public Health Conference Zürich/Switzerland, “Genomic Literacy”
Angela Brand, 31.08.2009, NUGO Montecantini Terme, Italy, “Nutrigenomics in the context of Public Health Genomics”
Angela Brand, 11.11.2009 SIGU Turjn/Italy, “Public Health Genomics in Europe – Assessment and Policy Development”
Angela Brand, 28.11. 2009 EUPHA Lodz(Poland, “Genomic Lizteracy from a Public Health Perspective”
Herman Van Oyen, 08.02.2010, Belgian PHGEN NTF : “Integrating genomics into public health: a challenge for the 21st Century”
Nuria Malats, 18.03.2010, Biomedica Aachen, “Epigenomics and Epidemiology : a good match”
Angela Brand, 18.03. 2010, Biomedica Aachen, “Epigenomics: the blueürint for Public Health Genomics”
Angela Brand, 09.05. 2010, Personalized Medicine in the Era of Public Health Genomics, Ickworth/UK, “PHGEN”
Angela Brand. 15.06.2010, PerMediCon Köln/Germany, Panel Personalized Medicine
Angela Brand, 29.06.2010, EDMA, Brussels, “Public Health Genomics – the future is being built today !”
Angela Brand, 23.09.2010, DGSMP Berlin/Germany, „Individualized Prevention“
Angela Brand, 27.09.2010, CDC Atlanta/USA, update on Public Health Genomics activites in Europe
Angela Brand, 07.10.2010, Forum Personalised Medicine EHFG/Austria, ”Viewpoint PHGEN II on Personalized Medicine and Healthcare”
Paola Testori-Coggi, 07.10.2010, Forum Personalised Medicine EHFG/Austria,”DG Sanco – view on the future of the Personalized Medicine in Europe”
Angela Brand, 26.10.2010, Polish PHGEN NTF Symposium Warsaw/Poland, “Development of Genomics and Personalized Medicine in the World”
Angela Brand, 12.11.2010, EUPHA Amsterdam/Netherlands, “Public Health Genomics goes personalized?”
Nuria Malats, 12.11.2010, EUPHA Amsterdam/Netherlands, “From environmental and genetic diversity to personalized healthcare: is it possible?
Murielle Brochud, 12.11.2010, EUPHA Amsterdam/Netherlands, “Pharmacogenomics and Personalized Healthcare”
Servaas Morree, 13.11.2010, EUPHA Amsterdam/Netherlands, “Host genetics variation in Chlamydia trachomatis infection: translation and valorization by the EU FP6 EpiGenChlamydia Consortium”
Jacques Scheres, 13.11.2010, EUPHA Amsterdam/Netherlands, “ECDC role in fighting infectious diseases in the field of Public Health Genomics”
Nicole Probst Hensch, 22.11.2010, Swiss PHGEN NTF Geneva/Switzerland, “Screening and Public Health Genomics”
Angela Brand, 22.11.2010, APOGEE/CanGeneTest Montreal/Canada, ”PHGEN II
Angela Brand, 17.01.2011, OncoTRack Meeting Berlin/Germany, “Public Health Genomics goes personalized”
Angela Brand, 18.01.2011, RIVM, Bilthoven/The Netherlands, “Public Health Genomics”
Angela Brand, 28.02.2011, FEBSX-Sys Innsbruck/Austria, “Public Health Genomics and Systems Biology”
Angela Brand, 28.03.2011, Canceromatics II conference, CNIO Madrid/Spain, “Public Health Genomics goes personalized – lessons learned from cancer genomics”
Angela Brand, 30.03.2011, Pricing and Reimbursement. Innovations in Healthcare – from Research to Market, EC Brussels/Belgium, “How much will it cost/how much will we pay?”
Angela Brand, 05.05.2011, FET Flagship Pilot. Fet 11, Budapest/Hungary, “ITFoM – IT Future of Medicine”
Angela Brand, 07.05.2011, Federation of the European Academies of Medicine (FEAM) Spring Conference Rome/Italy, “Public Health Genomics”
Angela Brand, 09.05.2011, APOGEE/CanGeneTest Meeting, Quebec/Canada, “The research agenda and approaches of the European Centre for Public Health Genomics”
Angela Brand, 16.05.2011, Lebenswissenschaften zwischen molekularer Medizin und Kulturwissenschaften, Inter-disziplinäres Colloquium Düsseldorf/Germany, „,Molekulare Medizin – ein Meilenstein in der Gesundheitsversorgung?“
Angela Brand, 17.05.2011, IFCC WorldLab – EuromedLab, Berlin/Germany, “Public health and biobanking – The role of public health genomics”
PHGEN I ended in March 2009. PHGEN II continued at Maastricht University and was led by Prof. Dr. Angela Brand. PHGEN II has officially ended on 30 November 2012 with the reporting period ending on 30 January 2013.
Follow us on TWITTER!
PHGEN II as a Success Story, Biobanks and Personalized Medicine
PHGEN II has been selected as one of the success stories funded by the EU heath programs. The detailed report can be found here. PHGEN II has also been mentioned in the report of the European Commission expert group on biobanks and can be found here. Further our project has been pubished in the European Science Foundation's 'Personalised Medicine for the European Citizen' and can be found here.
Meeting of European Alliance for Personalised Medicine
Commissioner Dalli (speech) and Cyprus Minister Mavroyiannis launched in Brussels on 18 September 2012 the manifesto by the newly-formed European Alliance for Personalised Medicine (EAPM), which brings together patient groups, academia, health professionals and industry, as well as the European Commission and the European Medicines Agency. This news has been covered by APM Health and the European Parliament Magazine. Click here for the picture of our PHGEN coordinator discussing with Commissioner Dalli.
During the final meeting in April 2012 in Rome, the PHGEN II European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies have been officially endorsed as the "Declaration of Rome 2012" by the European Member States as well as European key Institutions and Organizations such as EMA. The "Declaration of Rome 2012" has been published in the Journal "Drug Metabolism and Drug Interactions". It can be downloaded for free at the journal website here. Also a related editorial has also been published in the same journal which can be found at the journal website here. The "Declaration of Rome 2012" is the summary of the European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies produced in the form of 3 individual reports (QA, Provision & Use) by the PHGEN II consortium. These 3 parts can be accees below:
PHGEN II Extension Granted
Given the success of the project and realizing the deliverables go beyond the current deliverables, the PHGEN II project has been granted a 6 months cost netural extension by the EAHC. Therefore, the project will continue till the 30 November 2012. Originally the project was till 30 May 2012.
PHGEN II Final Meeting Rome
The PHGEN II final meeting (endorsement panel) took place in Rome, Italy. It was a success. Further information can be found here.
PHGEN II has released the definitions list which will be used as the guiding tools for the development of the guidelines. These constitute definitions developed during PHGEN I as well as new definitions. This can be found by clicking the link here.
The 3rd and final Steering Committee Meeting of PHGEN II took place on 23 February 2012 in Maastricht, The Netherlands. Further information can be found here.
ITFoM is one of six pilot projects in the European Future and Emerging Technologies Flagship scheme. These projects are vying for €1 billion funding from both the European Commission, Member States and other sources over ten years in order to generate a scientific revolution. Further information can be found from here.
Old information and news of PHGEN II can be found in the Archives here.
Public Health Genomics Journal
(Journal published in collaboration with GRaPH-Int)
'Public Health Genomics' is the first peer-reviewed international journal to focus on the translation of genome-based knowledge and technologies into public policy, disease prevention and the improvement of population health. It is a multidisciplinary bi-monthly forum containing conceptual and original research articles, editorials, reviews, short communications, country reports, case studies, viewpoints, news and various other features about the nature of public health genomics and related concepts.
For more details please visit http://www.karger.com/phg
PHGEN II is currently also developing a Wiki. This can be accessed here.
PHGEN II is coordinated by the Institute for Public Health Genomics (IPHG) at Maastricht University. The publication list contributed by partners of PHGEN II can be found here.
The IPHG coordinated the bachelor's program Public Health Genomics. The output of the successful course was a report made by the students with supervision from their supervisors. The report can be found here.
PHGEN II events have now officially ended.